Long-term impact of highly active antiretroviral therapy on HIV-related health care costs

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 1, 2001, Pages 14-19

  Keiser, Philip ^a,b   Nassar, Naiel ^a,b   Kvanli, Mary Beth ^b   Turner, Dianna ^b   Smith, James W ^a,b   Skiest, Daniel ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Cost; Cost benefit; HAART; HIV therapy; Outcomes

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; EMERGENCY TREATMENT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; OUTPATIENT CARE; PATIENT CARE; PRIORITY JOURNAL; VIRUS LOAD;

EID: 0035329587     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200105010-00003     Document Type: Article

References (19)

1. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
3. Impact of combination therapy for HIV infection on inpatient census
4. Guidelines for the use of antiretroviral agents in HIV-infected adults adolescents
5. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
6. HIV-I protease inhibitors. A review for clinicians
7. Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study
8. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital
9. Costs of HIV medical care in the era of highly active antiretroviral therapy
10. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland
11. The care of HIV-infected adults in the United States
12. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
13. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection
14. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
15. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
16. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
17. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
18. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients
19. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy